NO20054714L - Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom - Google Patents

Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Info

Publication number
NO20054714L
NO20054714L NO20054714A NO20054714A NO20054714L NO 20054714 L NO20054714 L NO 20054714L NO 20054714 A NO20054714 A NO 20054714A NO 20054714 A NO20054714 A NO 20054714A NO 20054714 L NO20054714 L NO 20054714L
Authority
NO
Norway
Prior art keywords
disease
procedures
preventing
cognitive impairments
alzheimer
Prior art date
Application number
NO20054714A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054714D0 (no
Inventor
Mark Steven Shearman
Mervyn Turner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054714D0 publication Critical patent/NO20054714D0/no
Publication of NO20054714L publication Critical patent/NO20054714L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20054714A 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom NO20054714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45458903P 2003-03-14 2003-03-14
PCT/GB2004/000983 WO2004080459A1 (en) 2003-03-14 2004-03-08 Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease

Publications (2)

Publication Number Publication Date
NO20054714D0 NO20054714D0 (no) 2005-10-13
NO20054714L true NO20054714L (no) 2005-11-16

Family

ID=32990914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054714A NO20054714L (no) 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Country Status (13)

Country Link
US (1) US20060241133A1 (ru)
EP (1) EP1605940A1 (ru)
JP (1) JP2006520371A (ru)
KR (1) KR20050109990A (ru)
CN (1) CN1794992A (ru)
AU (1) AU2004218871A1 (ru)
BR (1) BRPI0408295A (ru)
CA (1) CA2518886A1 (ru)
IS (1) IS8004A (ru)
MX (1) MXPA05009850A (ru)
NO (1) NO20054714L (ru)
RU (1) RU2005131845A (ru)
WO (1) WO2004080459A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
EP1971598A1 (en) 2005-11-21 2008-09-24 Amgen Inc. Beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
EA201100461A1 (ru) * 2008-09-11 2011-10-31 Амген Инк. Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
AU2011227511B2 (en) 2010-03-15 2014-02-20 Amgen Inc. Spiro-tetracyclic ring compounds as Beta - secretase modulators
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
WO1996033189A1 (en) * 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
EP0900086A4 (en) * 1996-05-07 2000-01-12 Merck & Co Inc IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
JP2002524402A (ja) * 1998-09-03 2002-08-06 ニューロンズ・リミテッド 神経保護
DE60022683D1 (de) * 1999-12-28 2005-10-20 Kaken Pharma Co Ltd Nervenschutzmittel
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

Also Published As

Publication number Publication date
IS8004A (is) 2005-08-29
US20060241133A1 (en) 2006-10-26
KR20050109990A (ko) 2005-11-22
EP1605940A1 (en) 2005-12-21
NO20054714D0 (no) 2005-10-13
BRPI0408295A (pt) 2006-03-07
MXPA05009850A (es) 2005-12-06
JP2006520371A (ja) 2006-09-07
WO2004080459A1 (en) 2004-09-23
RU2005131845A (ru) 2006-02-10
CN1794992A (zh) 2006-06-28
CA2518886A1 (en) 2004-09-23
AU2004218871A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
GB0225475D0 (en) Therapeutic agents
GB0005251D0 (en) Therapeutic compounds
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
GB0223038D0 (en) Therapeutic compounds
EA200400881A1 (ru) Азаарилпиперазины
SE0202462D0 (sv) Novel use
GB0318447D0 (en) Therapeutic agents
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
JO2282B1 (en) Oxazole derivatives
GB0225474D0 (en) Therapeutic agents
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
GB0112348D0 (en) Compounds
WO2004029031A3 (en) Therapeutic piperazine compounds
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
NO20051263L (no) Ny anvendelse av benzotiazolderivater
EA200401114A3 (ru) Замещённые гидроксиэтиламины
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser